RegeneRx Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGRX research report →
Price Chart
About the company
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue.
- CEO
- J. J. Finkelstein
- IPO
- 2003
- Employees
- 2
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on RGRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.05K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.01
- P/B
- -0.03
- EV/EBITDA
- -0.82
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1826.45%
- Net Margin
- -2249.84%
- ROE
- 60.86%
- ROIC
- 1654.75%
Latest fiscal year · YoY change
- Revenue
- $76.76K+0.0%
- Gross Profit
- $76.76K+9.5%
- Op Income
- $-1,402,000
- Net Income
- $-1,727,000-8.1%
- EPS
- $-1.00-7094.2%
- OCF Growth
- +5.0%
- FCF Growth
- +5.0%
- 52W High
- $0.16
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 4.73
- RSI (14)
- 48
- Avg Volume
- 21
No earnings-call transcripts are available for RGRX yet.
- Free Float
- 55.9%
- Shares Outstanding
- 1.50M
- Float Shares
- 836.25K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Williams Jones & Associates LLC | 140.00K | ▼ 10.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 3, 23 | Essetifin SPA | other | 3,750,000 |
| Jul 3, 23 | Essetifin SPA | buy | 0 |
| May 17, 22 | GOLDSTEIN ALLAN L | other | 480,000 |
| May 17, 22 | GOLDSTEIN ALLAN L | other | 480,000 |
| May 17, 22 | Bove Mauro | other | 240,000 |
| May 17, 22 | Bove Mauro | other | 240,000 |
| May 17, 22 | Noseda Alessandro | other | 240,000 |
| May 17, 22 | Noseda Alessandro | other | 240,000 |
| May 17, 22 | Elsey R Don | other | 290,000 |
| May 17, 22 | MCNAY JOSEPH C | other | 290,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RGRX coverage
Recent articles, reports, and earnings notes.
No research on RGRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGRX report →RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
prnewswire.com · Aug 15
RegeneRx Receives Stockholder Approval for Reverse Stock Split
prnewswire.com · Aug 7
RegeneRx To Extend Consent Solicitation Vote
prnewswire.com · Aug 1
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
prnewswire.com · Oct 6
RegeneRx Issues Letter To Stockholders
prnewswire.com · Jul 22
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
prnewswire.com · Jul 14
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
prnewswire.com · Jul 1
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
prnewswire.com · Jun 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.